摘要
有许多临床问题,即使是训练有素的医生也不容易回答。常用的诊断工具,是以评估认知功能障碍的神经退行性疾病为基础建立的临床标准。然而,疾病之间的鉴别诊断是困难的,特别是在早期阶段或非典型变种。当它仍然有可能使用一个适当的治疗时,这尤为重要。 为了解决这个问题,医生需要获得诊断测试的军工厂,如神经功能成像,允许更高的特异性临床评价。然而,诊断测试的可靠性从一个到下一个可能会有所不同,因此,一个给定的调查的诊断的有效性,必须估计通过从“真实”标准的“金标准”或基准测试比较获得的结果。虽然病理分析在广泛的疾病中被认为是的金标准,但是它不能被应用到神经系统过程。其他的方法可以提供解决方案,包括临床患者随访,创建一个数据银行或使用计算机辅助诊断算法。 在这篇文章中,我们讨论了与诊断效度分析相关不同的方法程序的发展和以使用碘-123-碘氟烷-单光子发射计算机化断层显像为基础介绍的运动障碍患者研究的一个自身经历。本章的目的是考虑到特定的神经退行性疾病的问题,从医生的角度来看探讨问题。
关键词: 阿尔茨海默病,计算机辅助诊断系统,痴呆,诊断准确,机器学习,神经成像,支持向量机。
Current Alzheimer Research
Title:Diagnosis of Neurodegenerative Diseases: The Clinical Approach
Volume: 13 Issue: 5
Author(s): Manuel Gómez-Río, Manuel Moreno Caballero, Juan Manuel Górriz Sáez and Adolfo Mínguez-Castellanos
Affiliation:
关键词: 阿尔茨海默病,计算机辅助诊断系统,痴呆,诊断准确,机器学习,神经成像,支持向量机。
摘要: There are a number of clinical questions for which there are no easy answers, even for welltrained doctors. The diagnostic tool commonly used to assess cognitive impairment in neurodegenerative diseases is based on established clinical criteria. However, the differential diagnosis between disorders can be difficult, especially in early phases or atypical variants. This takes on particular importance when it is still possible to use an appropriate treatment.
To solve this problem, physicians need to have access to an arsenal of diagnostic tests, such as neurofunctional imaging, that allow higher specificity in clinical assessment. However, the reliability of diagnostic tests may vary from one to the next, so the diagnostic validity of a given investigation must be estimated by comparing the results obtained from “true” criteria to the “gold standard” or reference test. While pathological analysis is considered to be the gold standard in a wide spectrum of diseases, it cannot be applied to neurological processes. Other approaches could provide solutions, including clinical patient follow-up, creation of a data bank or use of computer-aided diagnostic algorithms.
In this article, we discuss the development of different methodological procedures related to analysis of diagnostic validity and present an example from our own experience based on the use of I-123-ioflupane-SPECT in the study of patients with movement disorders. The aim of this chapter is to approach the problem of diagnosis from the point of view of the clinician, taking into account specific aspects of neurodegenerative disease.
Export Options
About this article
Cite this article as:
Manuel Gómez-Río, Manuel Moreno Caballero, Juan Manuel Górriz Sáez and Adolfo Mínguez-Castellanos , Diagnosis of Neurodegenerative Diseases: The Clinical Approach, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666151116141603
DOI https://dx.doi.org/10.2174/1567205013666151116141603 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry Multitarget-Directed Ligands: Innovative Chemical Probes and Therapeutic Tools Against Alzheimer's Disease
Current Topics in Medicinal Chemistry Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Central Selective Acetylcholinesterase Inhibitor with Neurotrophic Activity Structure-Activity Relationships of TAK-147 and Related Compounds
Current Medicinal Chemistry Easy Screening for Mild Alzheimer's Disease and Mild Cognitive Impairment from Elderly Speech
Current Alzheimer Research Meet the Editorial Board:
Central Nervous System Agents in Medicinal Chemistry Native Proteins in Organic Chemistry. Recent Achievements in the use of non Hydrolytic Enzymes for the Synthesis of Pharmaceuticals
Current Organic Chemistry Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Diabetes Type 4: A Paradigm Shift in the Understanding of Glaucoma, the Brain Specific Diabetes and the Candidature of Insulin as a Therapeutic Agent
Current Molecular Medicine Perspective on Acetylcholinesterase: A Potential Target for Alzheimer’s Disease Intervention
Current Enzyme Inhibition Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Mitigating Alzheimer’s Disease with Natural Polyphenols: A Review
Current Alzheimer Research Hypometabolism in Brain of Cognitively Normal Patients with Depressive Symptoms is Accompanied by Atrophy-Related Partial Volume Effects
Current Alzheimer Research NMDA Receptor Antagonists as Antidepressant and Antidementia Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry - Central Nervous System Agents Neurogenesis in the Adult Brain: Implications for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?
Current Alzheimer Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) γ-Secretase as a Therapeutic Target for Treatment of Alzheimers Disease
Current Pharmaceutical Design